REHOVOT, Israel ,
Dec. 21,
2023 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene
Ltd. (Nasdaq: EVGN) (TASE: EVGN), is gearing up for
participation in the JP Morgan 42nd Annual Healthcare
Week, scheduled to run from January 8 to 11,
2024, in San Francisco.
Biomica will also be taking part in the Biotech Showcase
conference.
Dr. Elran Haber, CEO of Biomica, will be available for
one-on-one meetings throughout the week, starting on Monday, January 8, and concluding on Thursday, January 11, 2024. Those interested in
scheduling a meeting with Dr. Haber can reach out to Biomica's
investor or public relations team."
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing PRISM system, a
proprietary computational platform powered by Evogene's MicroBoost
AI tech-engine. licensed from Evogene. Biomica aims to identify and
characterize disease-related microbiome entities and to develop
novel therapeutics based on these understandings. The company is
focused on the development of therapies for antibiotic resistant
bacteria, immuno-oncology, and microbiome-related gastrointestinal
(GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq:
EVGN, TASE: EVGN).
For more information, please visit www.biomicamed.com.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
View original
content:https://www.prnewswire.com/news-releases/biomica-ceo-set-to-attend-jp-morgan-healthcare-week-in-san-francisco-january-8-11-2024-302020942.html
SOURCE Biomica Ltd.